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Abstract: This article reviews issues related to a major challenge to the field for obsessive–
compulsive disorder (OCD): improving access to cognitive-behavioral therapy (CBT). Patient-
related barriers to access include the stigma of OCD and reluctance to take on the demands of 
CBT. Patient-external factors include the shortage of trained CBT therapists and the high costs 
of CBT. The second half of the review focuses on one partial, yet plausible aid to improve 
access – prediction of long-term response to CBT, particularly using neuroimaging methods. 
Recent pilot data are presented revealing a potential for pretreatment resting-state functional 
magnetic resonance imaging and magnetic resonance spectroscopy of the brain to forecast OCD 
symptom severity up to 1 year after completing CBT.
Keywords: follow-up, access to treatment, relapse, resting-state fMRI, magnetic resonance 
spectroscopy
Introduction
In the realm of obsessive–compulsive disorder (OCD), expansion of patient access to 
cognitive-behavioral therapy (CBT) is a major clinical challenge. The first half of this 
review summarizes this problem and some attempts at solution. We mostly comment 
on the situation in the US, especially California, although similar conditions exist 
elsewhere. The second half of the paper focuses on one aspect of CBT – post-treatment 
follow-up. Effective prediction of long-term (or even short-term) response to CBT or 
other OCD treatments is lacking. Improved prediction would partially alleviate the 
access issue by enabling better allocation of scarce therapist and financial resources 
and by increasing confidence of patients, prescribers, and third-party payers in CBT.
Factors limiting access to CBT for OCD
CBT, particularly intensive daily CBT,1,2 is highly effective for OCD3 with response 
rates of 50%–70%.4,5 CBT offers comparable symptom improvement and lower relapse 
than time-limited pharmacotherapy.6–12 In contrast to serotonin-reuptake inhibitors 
(SRIs) or other drugs, moreover, CBT has faster initial response; a response that typi-
cally persists past the end of treatment (ideally, for life); and no physical untoward 
“side-effects”. Finally, through CBT, a patient acquires self-mastery, insights, and life 
skills not imparted by medication. Thus, CBT is established as a first-line, evidence-
based treatment for OCD.13
OCD treatment generally is underutilized14 and, compared with SRIs, CBT is 
vastly underused. Few OCD patients actually receive CBT:15–17 only ~5% of adult 
patients in British and American surveys.18,19 This is unfortunate because there are 
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substantial numbers of OCD patients who respond to CBT 
or to combined CBT and medications who do not respond 
to medications alone. That is, there are patients who will 
not get better if they do not receive CBT. At present, there 
is no way to tell a priori if a patient will be a responder or 
a non-responder. There is also a subgroup of patients who 
might benefit from medications but who refuse to take them, 
leaving CBT as the only major treatment option. Thus, many 
patients who could benefit from CBT are not receiving it.
Patient-related factors limiting 
access
Numerous sufferers of OCD, wittingly, willingly, or not, deny 
themselves access to CBT. The full range of insight into one’s 
own condition is represented in OCD; thus, some patients 
have low insight.20 It may not occur to such individuals to 
seek treatment without considerable prodding from com-
miserating friends and family. Many other individuals are 
all too aware or at least suspicious that something is wrong, 
but are powerfully dissuaded from seeking treatment (even 
led to denial) by the stigma of OCD. As for mental illness 
generally, this stigma has abated in recent decades, but still 
very much exists. Other sufferers are not aware of CBT as 
a treatment option. Yet others are, to varying degrees, aware 
but doubtful of the efficacy of CBT. They perhaps may be 
categorically dismissive of psychotherapy “talking cures”. 
A further group may have a more or less concrete grasp of 
what CBT entails and eschew it for that every reason. That 
is, they are reluctant to take on the work and stress of CBT, in 
particular the exposure to and confrontation with one’s deep-
est fears.21 Such attitudes may constitute one form of insuf-
ficient “motivation”. Others may be insufficiently motivated 
because they feel their OCD is not severe or life-disrupting 
enough to merit treatment. All these factors in the minds of 
prospective patients can militate in varying combinations to 
forestall reaching out to get badly needed help.
A second class of prospective patients are disqualified 
from or poorly suited for CBT based on specific psychiatric 
comorbidities. If a patient’s depression is too severe, then 
it is likely he or she will not muster the energy or have 
the motivation required to practice CBT exercises. Hence, 
prognosis is poor and many therapists choose not to work 
with such patients until their depression is better managed 
with medications and/or psychotherapy for depression. The 
same applies for bipolar patients currently in the depressive 
pole. Bipolar patients experiencing mania or hypomania, 
in contrast, are poor candidates for CBT because they are 
feeling too good! Hence, they are unlikely to experience the 
fear and anxiety generated during CBT exposure exercises, 
emotions thought to drive recovery. In a similar vein, patients 
with currently active substance abuse are poor candidates 
for CBT. For them, the effects of the substances may inter-
fere with their ability to experience the requisite anxiety 
or distress necessary for success with exposure exercises. 
Comorbid psychoses can also preclude treatment with CBT. 
Those with severe personality disorders or otherwise severe 
characterological disturbances are generally poor candidates 
for OCD-focused CBT. These comorbidities temporarily or 
permanently exclude a portion of the psychiatric population 
from CBT.
Patient-external factors limiting 
access
One main reason for the underuse of CBT is the lack of 
highly trained CBT therapists in the health care system.22–25 
Many OCD patients who desire CBT cannot get in to see 
a qualified therapist within a reasonable timeframe. Most 
graduate programs in psychology and allied fields include 
only minimal training in CBT and no training in exposure and 
response prevention (the best-established form of CBT) in 
their standard curricula. Most therapists are currently trained 
by senior colleagues or learn on their own at their practices. 
A consequence of the shortage of therapists is that the clin-
ics that do offer CBT services often maintain long waitlists. 
Therefore, many patients who would benefit from CBT are 
not receiving it, or only after a long delay.
Another limiting factor is the cost of CBT. CBT is chiefly 
administered in “weekly” or “intensive daily” modalities. In 
the former, the patient undergoes one 1–2-hour session every 
week for 12–14 weeks; in the latter, the patient undergoes 
treatment for 4–5 hours, 4–5 days per week for 3–6 weeks. 
For both modalities, the patient is also required to perform 
“homework” exercises outside the sessions. Either way, there 
are heavy demands on the patient’s and the therapist’s time. 
As the therapist is normally a highly trained professional, 
substantial fees can incur. This is in addition to costs to the 
patient in time away from work, school, raising children, 
and other life activities. Some patients judge these costs to 
be unsustainable and opt for drug treatment instead, even if 
in the long run they end-up spending more on medication. 
Thus, cost can be a substantial barrier to CBT.
The following discussion of CBT and health insurance 
is most relevant for US practitioners. But it does have some 
relevance for clinicians elsewhere, for example, in countries 
where prescription of more than a standard amount of CBT 
(eg, ten sessions) has to be justified to a public health agency. 
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Health insurance can mitigate the costs of CBT. Many 
patients prefer to pay for CBT through their insurance, 
especially since they are paying premiums for it, directly or 
indirectly through payroll deduction. But not all patients have 
health insurance, or enough insurance, or the right kind of 
insurance. Generally, in the US, if a patient has a preferred 
provider organization type health insurance plan, there will 
be coverage for CBT, although it may only pay for 1/3 to 2/3 
of the costs. For more economical plans, that may not be the 
case. Some patients are not aware that insurance even covers 
CBT. Access to the Internet has ameliorated this problem 
recently, but it is still challenging and confusing to determine 
exactly what is covered and what not. Insurance reimburse-
ment for CBT is not universal and can be inadequate. It also 
varies across policies and is often opaque and byzantine 
in complexity, which often poses too difficult a task for 
someone with OCD who may be easily overwhelmed. It is 
typically easier to obtain coverage for prescription drugs than 
for CBT. Some patients with insurance cannot afford even 
the residual costs (deductibles, co-pays, etc) after insurance, 
although therapists may offer discounts in such cases. For 
patients seeking “in-network” coverage, insurance compa-
nies will provide them a list of therapists who self-report 
that they use CBT treatment modalities. However, there is 
no universal credential for CBT aptitude, and many patients 
find that these therapists have minimal knowledge of, much 
less expertise with, CBT. Still other patients do not wish to 
pay for CBT through insurance even if they can, for fear of 
compromising privacy and other reasons. Many therapists 
do not accept insurance due to the complexities and limita-
tions and because reimbursement rates are too low. Even 
when claims are awarded, payment may be protracted. Small 
private practices are especially impacted by the bureaucratic 
hindrances associated with third-party payers. While large 
hospitals may maintain entire departments (eg, “utilization 
review”) tasked with justifying proposed treatments to 
third-party payers and collecting reimbursement therefrom, 
fewer private therapists have the time and resources for such 
activity. This is a major reason why many small practices 
do not accept insurance. After all, for hourly professionals, 
their time is their livelihood. Even in large centers, many 
clinical staff can spend nearly as much time filling out forms 
or on the phone with insurance companies trying to establish 
“medical necessity” as they do actually treating patients, 
a deplorable state-of-affairs. Insurance providers argue that 
claim-resistant practices actually benefit the patient popu-
lation by way of “cost containment”, but costs could also 
be contained by accepting lower profits and/or improving 
efficiency, without denying needed services to patients. In 
sum, insurance renders CBT accessible for many patients, 
but substantial issues remain.
Responses of the field to CBT 
access issues
Certain patient-related barriers to access, including lack 
of insight, stigma of OCD, and awareness of CBT and its 
efficacy, can be approached in part by the methods of public 
relations. The International Obsessive–Compulsive Disorder 
Foundation (IOCDF, http://iocdf.org/) has done tremendous 
work in these areas over the years. The advent of the Internet 
has also helped reduce the stigma of OCD and has allowed 
many patients to gain anonymous access to sensitive informa-
tion about OCD and its remediation. Perhaps ongoing public 
relations work could be supplemented by specialized outreach 
efforts targeting patients who are frightened of embarking on 
a regimen of CBT. The latter could be particularly effective 
if patients who have successfully undergone CBT treatment 
could testify to its benefits, and encourage other prospective 
patients.
In the case of patients insufficiently motivated to undergo 
CBT, often when the disease has grown to unmanageable 
severity and one or more other forms of treatment have failed, 
some patients will finally opt for CBT. One would, of course, 
rather that they not wait that long. This has driven efforts to 
propose motivational therapy before a regimen of CBT for 
appropriate patients. Similarly, for patients with depression, 
bipolar disorder, substance abuse, and/or psychoses, these 
conditions can be treated first with medication and/or psy-
chotherapy before inaugurating CBT for OCD.
The issue of the shortage of trained CBT therapists is 
being countered in part by the IOCDF, which offers CBT 
training for licensed therapists by top leaders in the field 
through their Behavior Therapy Training Institute (BTTI) 
http://iocdf.org/professionals/training-institute/btti/ three 
times per year at relatively modest cost due to partial subsi-
dization through the foundation. However, many more expert 
therapists are needed than are generated by the BTTI alone. 
It would be helpful if training in exposure and response 
prevention was mandatory for graduate programs in clinical 
psychology and allied disciplines, at least in some schools.
Issues involving patients having insurance coverage for 
CBT, insufficient reimbursement of CBT costs, limits on 
the amount of CBT covered, bureaucratic burden in secur-
ing coverage and reimbursement are traditionally addressed 
(adequately or not) in the arena of public health policy 
through litigation (eg, class-action lawsuits), lobbying, and 
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political activism. Part of this is subsumed under efforts to 
improve access to mental health services, generally. Past 
successes have included the passage of mental health par-
ity laws in the US and California requiring that third-party 
benefits for mental health be no lower than those for medical 
conditions. Unfortunately, through technicalities, third-party 
payers have been able to sidestep the spirit of these laws. 
Similarly, the enactment of the Affordable Care Act in the 
US has not solved all issues related to cost and insurance, 
although it has enabled some OCD patients to gain access 
to CBT because they can no longer be denied coverage on 
grounds of pre-existing condition. Given the overwhelming 
financial and political power of interests vested in minimizing 
and reducing outlays for health insurance claims, it would 
likely require substantially higher sustained activism by 
patients and professionals and their organizations to bring 
about the needed reforms. They would thereby need to remain 
vigilant of perils of compromise and co-optation.
A perhaps more promising innovative response of the 
field to combined cost and therapist-availability issues has 
been to investigate alternative modalities of CBT that are 
less time intensive for the therapist. Group – as opposed 
to traditional individual – CBT has recently been studied 
intensively.26–30 These group CBT studies are reporting 
efficacies that are sometimes slightly less, but generally 
comparable to responses to individual CBT and to SRIs. 
Telephone- or Internet-based CBT has also been explored 
in multiple studies in adult and pediatric OCD.31–36 These 
studies, again, report efficacy comparable to traditional 
treatment modalities. Such approaches appear to offer par-
ticularly practical solutions to the challenges of cost and 
therapist availability.
Prediction of post-CBT outcomes  
in OCD
The remainder of this review concerns a circumscribed aspect 
of the issue of access to CBT: prediction of post-treatment 
outcome. Effective prediction of long-term (or even immedi-
ate) outcome does not exist for any OCD treatment, including 
CBT. If developed, then such would alleviate patient-related 
and patient-external barriers to CBT. In particular, if we knew 
better in advance who will respond (especially long-term) to 
CBT and who will not, it would enable more efficient pre-
scription of CBT and superior allocation of scarce therapist 
resources. Moreover, a clinician could advise an individual 
patient of the odds of success of CBT before undergoing 
therapy and/or odds of relapse after therapy. Patients with 
poor odds could be referred to other forms of treatment. 
Although every patient with OCD – including those for 
whom poor response is foreseen – should be allowed to try 
CBT if he or she so prefers. But those with good prospects 
could be more strongly encouraged to try CBT, even against 
initial reluctance. If we had post-treatment indicators whether 
relapse is likely or whether benefits achieved will probably be 
maintained, we would be able to lengthen CBT or to divert to 
an alternative therapy (and justify these choices to third-party 
payers). In either case, clinicians, including psychiatrists and 
general practitioners, would be more inclined to prescribe 
CBT alongside or instead of medications to those patients 
with good prospects.
Relapse after CBT for OCD
As the effectiveness of CBT is well documented and beyond 
doubt, a more useful clinical question is not who will respond 
to treatment but rather who will remain well and/or continue 
to improve after treatment. Although, as mentioned, relapse 
is less common after CBT for OCD than after discontinu-
ation of medication, post-treatment relapse still occurs in 
approximately 20% of CBT patients.37–43 Across studies, 
relapse rates range widely from 0% to 50%,7 but relapse can 
occur even when an explicit relapse-prevention component 
is included in the CBT regimen. Wide variability in relapse 
may relate to differences in treatment parameters, patient 
characteristics, and even the definition of relapse.12 Given the 
substantial time commitment of CBT, its expense, the high 
demand yet shortage of qualified therapists, and consequent 
long waiting lists, relapse represents an unanticipated yet 
untoward misallocation of resources and a heavy burden on 
patients, clinicians, and public health. Sadly, the factors that 
predict who will retain improvement and who will relapse are 
unknown. Thus, the question is significant: What predicts who 
will remain in remission and who will relapse after treatment? 
Moreover, adequate studies have not been done to determine 
the duration of treatment optimal for preventing relapse.44
Despite the clinical importance of determining to what 
extent worsening of OCD after treatment should be consid-
ered “relapse”, remarkably little research has addressed this 
topic. Several treatment studies have investigated relapse, 
using a range of definitions. These include 50% or greater 
worsening of Yale–Brown Obsessive Compulsive Scale 
(Y-BOCS), Y-BOCS $19, or a Clinical Global Impression-
Improvement (CGI-I) score of “much worse” or “very much 
worse”;10 worsening of $5 points on Y-BOCS, Y-BOCS of 
$20, and at least a 1-point increase on CGI-I;45 return to 
pretreatment Y-BOCS or a $1-point worsening on CGI-I;46 
$5-point worsening on Y-BOCS or investigator’s judgment of 
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unsatisfactory treatment effect;47,48 or return to pretreatment 
severity on the CGI-Severity (CGI-S) scale.11,49 It would be 
beneficial for the field to reach a uniform standard definition 
of relapse.
Clinical predictors of relapse
While there is some evidence for predictors of short-term 
response to treatment,50–52 fewer studies have addressed 
the equally important question of sustained response, or, 
conversely, worsening after treatment.53,54 Several natural-
istic follow-up studies have sought to identify predictors 
of symptom course.29,55–60 One study followed a cohort for 
21 months after a 12-week randomized trial of group CBT 
or fluoxetine.58 Comorbid affective disorders, any comorbid 
psychiatric condition, and illness duration were associated 
with higher post-treatment OCD symptoms. A study that fol-
lowed an OCD cohort treated with 12 sessions of group CBT 
for 2 years found that full remission of symptoms at the end of 
treatment protected against relapse.29 Another study followed 
patients for 6 years after receiving CBT with clomipramine or 
placebo. Greater amount of CBT, better homework compli-
ance, and improvement at the end of treatment were associ-
ated with better outcomes.44 Likewise, in a meta-analysis of 
pediatric OCD, severity of illness, comorbid diagnoses, and 
poor initial treatment response were associated with worse 
longitudinal course.60 However, another study that followed 
patients 6–8 years after CBT plus fluvoxamine or placebo did 
not find an association between short-term treatment response 
and long-term outcome.59 In aggregate, naturalistic studies 
have examined group or individual CBT, alone or combined 
with pharmacotherapy, over follow-up periods ranging from 
2 to 30 years. Predictors of long-term success varied widely 
and included shorter duration of OCD, lower severity, lack of 
psychiatric comorbidities, more CBT, and better CBT home-
work compliance. Across studies, the most consistent finding 
is that shorter illness duration predicts better outcome. While 
this counsels early intervention, it cannot be the sole factor, 
as response to CBT occurs in many long-term untreated 
OCD patients and not in every short-term patient. A few 
studies pointed to full remission as a predictor of continued 
post-treatment well-being. While remission is increasingly 
aspired to as a treatment goal,61 complete remission remains 
rare in adult OCD. Moreover, many demographic factors, and 
even duration of illness, may be useful prognostically but are 
not modifiable, reducing their clinical utility. For example, 
the individual who is seeking treatment but has already had 
the illness for many years cannot “turn back the clock”. In 
principle, predictors based on psychometric instruments 
(or neurocognitive profiles) may be less reliable than objec-
tive measures (if such can be identified) as the former are 
highly effort- and, in some cases, evaluator-dependent. Thus, 
none of the above diverse endpoints has been adopted as a 
reliable clinical predictor. Moreover, the above results say 
little about brain mechanisms of relapse prevention.
Brain-based predictors of relapse
Prognostic biomarkers of relapse, in contrast, could lend more 
objectivity to clinical decision-making, while informing on 
possible brain mechanisms. Pretreatment signs of relapse, 
for example, could help determine whether an alternative 
treatment should be pursued, while post-treatment signs 
could help clinicians decide whether additional (or different) 
treatment is warranted. This would help alleviate the issue 
of the shortage of qualified CBT therapists since available 
therapists could be assigned to cases with higher prospects 
of success. Patients with low prospects on CBT could be 
treated with medication or other therapies. By increasing 
the long-term efficacy of CBT, an accurate biomarker test 
might even encourage third-party providers to cover CBT 
more readily, thus increasing access for patients who cannot 
afford it. Ie, an insurance company or a public health care 
agency with power to restrict or deny payment for or access 
to CBT sessions will more likely view such sessions as a 
“good investment” and therefore authorize a course of CBT 
if objective biomarker signs point to significant positive 
response (especially long-term) for an individual patient. 
Candidate biomarkers include safe, non-invasive, in vivo 
electroencephalography or magnetic resonance imaging 
(MRI)-based measures of brain-electric activity, structural 
morphometry or connectivity, functional connectivity, or 
neurochemical profiles. If such endpoints can be associated 
with relapse prior to treatment, then they could help deter-
mine if alternative therapy should be pursued.
Neuroimaging measurements of brain functional and 
metabolic activity are logical targets for putative biomarkers 
of clinical outcome. (For readers unfamiliar with neuroim-
aging, we recommend a review62 aimed at non-imaging 
clinicians.) Multiple studies associate OCD with regional 
hyperactivity, particularly in the familiar frontostriatal OCD 
brain circuits.63,64 One popular neuroimaging modality used 
to measure functional activity is resting-state functional 
MRI (rsfMRI) based on the blood oxygen level-dependent 
(BOLD) effect. The BOLD effect measures the oxygenation 
of hemoglobin in the blood in the tissue scanned. Neurons 
fire more when active, consume more oxygen when they 
fire, and extract this oxygen from the blood, changing its 
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paramagnetic properties. This results in a BOLD signal 
within the magnetic field. Therefore, a stronger BOLD effect 
in a given volume of brain tissue suggests higher neuronal 
activity in that volume. fMRI divides the brain into a 3D 
grid of thousands of small (usually 2–3 mm3) blocks, called 
volume elements or “ voxels”, and measures the BOLD effect 
in each. With “task” fMRI, usually the patient is perform-
ing an assigned task, eg, viewing a stimulus or performing 
a neurocognitive test. In this way, task fMRI detects which 
parts of the brain are active during each specific task. 
 rsfMRI is collected when there is no task; rather, the patient 
lies quietly in the scanner but does not go to sleep. It turns 
out the brain is still quite active in this state. In rsfMRI 
analysis, one calculates the correlation coefficients between 
the BOLD activities of each pair of voxels across the run-
time of the scan as a measure of ‘functional connectivity’. 
Alternatively, one can calculate across anatomically- or 
functionally-defined regions. Such analyses have revealed 
that the brain is divided into a number of functional networks 
of interconnected anatomic regions. Many of these networks 
that show high connectivity at rest are the same as those that 
activate during specific tasks. This has been demonstrated 
in that performance of these tasks outside the scanner typi-
cally correlates with the intrinsic resting-state connectivity 
of the network involved in processing this task.65 Why are 
these networks active at rest? It may be due to the fact that 
there are spontaneous low-frequency fluctuations in these 
networks – even though they are not in use, every so often 
they spontaneously fire together (neurons that “fire together 
wire together”).66 Moreover, as OCD patients live very 
much “in their heads”, overthink, are subjected to intrusive 
obsessive thoughts, etc, it is plausible that they could also, 
or alternatively, exhibit abnormal rsfMRI activity due to the 
abnormal activity in the scanner. Indeed, fMRI studies have 
detected aberrant network connectivity in frontostriatal and 
parietal regions that may contribute to OCD symptoms.67,68 
Below we report on our research involving rsfMRI and long-
term post-CBT outcome in OCD.
Another imaging modality, proton magnetic resonance 
spectroscopy (MRS), has also been applied to OCD.69 In 
MRS, one or more (usually larger, maybe 3–4 cc) voxels 
in targeted brain regions are stimulated with a (brief, non-
harmful) pulse of radiofrequency radiation from the scan-
ner headcoil. This pulse is absorbed by the hydrogen nuclei 
(protons) in the various biomolecules (“metabolites”) in 
the tissue, which promotes the protons into an energetically 
excited state. Over 10s to 100s of milliseconds, these protons 
then relax back to their initial unexcited state. As they do 
this, they release the energy they had absorbed. The liberated 
energy is picked up by the coil and registered as an electri-
cal voltage (signal) read by the scanner. The key to MRS is 
that the protons in each different metabolite absorb and then 
release energy at a slightly different frequency. Thus, the 
mix of frequencies in the coil signal reveals which species 
of metabolites are present in the tissue. The “MR spectrum” 
is a plot of the signal as a function of the frequency and 
consists of a series of “peaks”. The location of each peak on 
the frequency axis tells which metabolite the signal arises 
from. The size of the peak is proportional to the concentra-
tion of the metabolite in the voxel. It turns out that, of the 
thousands of biomolecules in the brain, only 5–6 are easily 
measured with conventional clinical MRS, ie, at scanner 
field strengths of 1.5–3 Tesla (T). Fortunately, these 5–6 are 
physiologically significant metabolites, in particular, ones 
related to brain-energy metabolism. From positron emission 
tomography studies, it is known that specific brain regions 
are energetically hyperactive in OCD, and this hyperactivity 
reduces shortly after treatment, including CBT (reviewed in 
O’Neill et al70 and Saxena et al71,72). It is thus reasonable to 
anticipate that MRS metabolites in these regions are sensitive 
to OCD and/or its treatment. Indeed, in prior work, we70,73 
and others (reviewed in Brennan et al69) found differences in 
levels of MRS-detectable metabolites between OCD patients 
and healthy controls, as well as changes in metabolite levels 
immediately following OCD treatment, including CBT. 
Below we report on our research involving MRS and longer-
term post-CBT outcome in OCD.
Both rsfMRI and MRS are readily performed on stan-
dard clinical MRI scanners. MRS can sample most single 
brain regions at a resolution of 3–4 cc in 5–10 minutes. In 
the same time span, rsfMRI can sample the entire brain at a 
resolution of 2–3 mm. With some effort, these procedures 
can be replicated across different scanners, lending them 
for use in large, multisite clinical trials. If rsfMRI and/or 
MRS endpoints reliably predicting short- and/or long-term 
response to CBT can be identified, then these properties 
will ultimately suit them for actual use in clinical settings. 
Reliable findings could also set the stage for testing different 
treatment durations to reduce risk of relapse.
A pilot rsfMRI correlate of post-CBT 
outcome
To give an idea of the flavor and potential of neuroimaging 
to predict CBT outcomes, in this section we present some of 
our recently published rsfMRI data.74 In the next section, we 
present original MRS data from the same pilot study. Data 
Psychology Research and Behavior Management 2015:8 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
217
CBT access and post-treatment follow-up for OCD
4.4
A B
4.2
12
9
6
3
0
−3
3.0 3.4 3.8 4.2
−6
−9
4.0
3.8
3.6
3.4
3.2
+7.5%
P<0.05
permutation
testing
r=+0.65
P<0.005
Spearman
3.0
Pre-CBT
S
m
al
l-
w
o
rl
d
n
es
s,
 A
U
C
f/
u
-p
o
st
-C
B
T
 Y
-B
O
C
S
 c
h
an
g
e
Post-CBT
Whole-brain BOLD rsfMRI graph theory Whole-brain BOLD rsfMRI graph theory
Pre-CBT small-worldness, AUC
Figure 1 A pretreatment brain imaging predictor of long-term treatment response of OCD.
Notes: (A) Values of the resting-state fMRI (rsfMRI) graph theory parameter small-worldness (a metric of brain information transfer efficiency) in a pilot sample of 17 adult 
OCD patients within 1 week before (pre; open symbols) and 1 week after (post; filled symbols), 4 weeks of intensive daily CBT. Sixteen of 17 patients (2 minimally) exhibited 
pre-to-post increase in small-worldness (group-mean 7.5%, P,0.05 permutation testing). (B) For same sample, change in Y-BOCS total score measuring severity of core 
OCD symptoms, expressed as score at post-CBT follow-up minus score immediately after completing CBT. This is plotted as a function of pre-CBT small-worldness. Patients 
with higher pre-CBT small-worldness had worsening of OCD symptoms (positive change) at follow-up while patients with initially low small-worldness had improvement in 
symptoms (negative change) (r=0.65, P,0.005). Relapsers ($5-point increase in Y-BOCS; triangles) had above-average pre-CBT small-worldness. Thus, rsfMRi graph theory 
may have some ability to predict long-term treatment response in OCD.
Abbreviations: AUC, area under the curve; BOLD, blood oxygen level-dependent; OCD, obsessive-compulsive disorder; rsfMRi, resting-state functional magnetic resonance 
imaging; fMRi, functional magnetic resonance imaging; CBT, cognitive-behavioral therapy; Y-BOCS, Yale-Brown Obsessive-Compulsive Scale.
from both modalities were acquired in a larger investigation 
of intensive outpatient CBT for adult OCD in a subcohort 
of 17–19 patients (aged 21–50) examined in post-treatment 
follow-up. These patients were reevaluated with multiple 
clinical instruments at times ranging 1–12 months (mean 
5.6±4.5 months) post-CBT. For each subject, rsfMRI and 
MRS were co-acquired within 1 week prior to initiating 
treatment and again within 1 week after finishing treatment. 
Scans were performed in a 3-T Siemens Trio scanner using 
a 12-channel phased-array headcoil.
Whole-brain BOLD rsfMRI was acquired using an 
8-minute echo-planar imaging sequence (repetition time/
echo time =2,000/25 milliseconds, flip angle =78°, voxels 
3×3×3 mm3, 1 mm gap). Subjects were instructed to rest 
with eyes closed, to remain as still as possible, and not to 
sleep. rsfMRI data were analyzed with graph theory. Graph 
theory has recently yielded impressive results in the analysis 
of brain connectivity networks.75 In graph theory, the fMRI 
dataset is represented abstractly as a brainwide geometric 
network or “graph” of (in our case 160) anatomical “nodes” 
or network vertices. A node consists of a clump of contiguous 
fMRI voxels all in the same predefined brain region. A single 
“edge” is drawn on the graph between each pair of nodes that 
have above-threshold functional connectivity (ie, internode 
BOLD activity correlation coefficient), after partialing-out 
noise contributions. One then calculates various parameters 
that characterize the shape or “topology” of the resulting 
graph and, if successful, the organization of the underlying 
brain network. These parameters answer questions such as: 
Do nodes on average have many connections or few connec-
tions? Are nodes mostly connected with their near neighbors 
or with other distant nodes? The most interesting graph theory 
parameter in our findings was “small-worldness”. Like a “hub 
and spoke” city subway system that overlays local lines mak-
ing frequent stops with express trains having fewer stops, a 
network with small-world architecture features dense local 
connections alongside sparser remote connections between 
nodes. This pattern is highly efficient for information transfer 
in the brain.76
In our pilot sample, we found that group-mean small-
worldness rose a modest but significant amount after CBT 
(7.5%, P,0.05, with permutation tests, controlling for 
motion; Figure 1). Small-worldness increased in 16 of 
17 patients (though in 2 cases only minimally). Patients who 
already had high pre-CBT small-worldness showed the least 
increase. Moreover, such patients were most likely to experi-
ence worsening of OCD symptoms at follow-up ( Figure 1). 
The six patients who qualified as post-CBT relapsers 
($5 points increase in Y-BOCS total score relative to score 
at discharge) had above-average pre-CBT small-worldness. 
There have been few prior graph theory studies of OCD, 
but one77 revealed below-normal small-world architecture 
in untreated OCD patients. A second study found that 
small-worldness increased in OCD after SRI medication.78 
Combining these results with ours suggests that at least some 
OCD patients have below-normal efficiency of brain informa-
tion processing. Raising this efficiency may be one CBT- or 
drug-mediated path to recovery from OCD (or, alternatively, 
a side benefit of recovery). But OCD patients who already 
have efficient brains may be more liable to relapse. One 
highly speculative explanation of this observation is that OCD 
“hi-jacks” a patient’s mental faculties as part of  symptom 
fulmination. More efficient cognitive faculties plague 
some OCD patients who find themselves misusing these 
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Figure 2 Sagittal MRi of pregenual anterior cingulate and its proton magnetic resonance spectrum.
(A) Sagittal T1-weighted MRi of the human brain showing location of 15×15×15 mm3 proton magnetic resonance spectroscopy (MRS) acquisition voxel (yellow square) in the 
pregenual anterior cingulate cortex (pACC). (B) Sample raw (jagged gray), baseline (light gray), and fit (solid red) MR spectra acquired from the pACC. The MR spectrum 
is a plot of the intensity of radiofrequency signal (ordinate axis) vs signal frequency (abscissa) in parts-per-million (ppm). The size (area under the curve) of each peak in the 
spectrum is proportional to a different biochemical species (metabolite) or small family of chemically related metabolites in the MRS voxel. The peak marked “Cr+PCr” at 
3.02 ppm represents the sum of the energetic neurometabolites creatine and phosphocreatine. in our OCD pilot sample, pretreatment Cr+PCr level in pACC was predictive 
of OCD core and other symptoms at post-treatment follow-up.
Abbreviations: Cr, creatine; OCD, obsessive-compulsive disorder; MR, magnetic resonance; MRi, magnetic resonance imaging; PCr, phosphocreatine.
faculties to conceive of more numerous and sophisticated 
obsessions, rituals, and avoidance strategies, all of which 
incline to relapse. Another possibility is that for CBT to have 
enduring effects, there needs to be a reorganization of net-
works in the direction of increased efficiency. Those with high 
small-worldness are already at their “ceiling” and thus further 
reorganization cannot occur. Although they may experience 
diminished OCD symptoms from pre- to post-treatment, they 
cannot maintain this new state because this change was not 
contemporaneous with a reorganization of the network. In 
any case, these findings hint at a possible ability of rsfMRI 
graph theory to discriminate different subtypes of patients 
in terms of post-CBT response.
A pilot MRS correlate of post-CBT 
outcome
MRS was acquired from the midline (ie, average of left 
and right hemispheres) pregenual anterior cingulate cortex 
(pACC). On sagittal brain MRI, the pACC lies just anterior to 
the corpus callosum (Figure 2). Water-suppressed MRS was 
acquired with a Siemens-product point-resolved spectros-
copy pulse-sequence (repetition time/echo time =2,000/30 
milliseconds, 96 repetitions, voxel dimensions 15×15×15 
mm3, runtime 3:20). Each run was immediately followed 
by an identical second-run (eight repetitions only) with 
water-suppression turned off. Spectra were fit offline with 
the LCModel commercial software package.79 Among other 
common proton metabolites, the combined levels of creatine 
(Cr) and phosphocreatine (PCr) were assayed. (These two 
metabolites are typically measured together, since their peaks 
in the MR spectrum are overlapping and poorly segregated 
and since the two compounds are biochemically coordinated). 
Metabolite levels were adjusted for the amount of cerebrospi-
nal fluid in the MRS voxel (a potential confound), quantified 
relative to the unsuppressed water signal (which has a known 
concentration), and expressed in Institutional Units.
A sample spectrum with Cr+PCr peak at a frequency of 
3.02 ppm is seen in Figure 2. As shown in Figure 3, pre-CBT 
Cr+PCr in pACC correlated significantly and negatively with 
Y-BOCS at follow-up (r=−0.54, P,0.05, Spearman); that is, 
patients with higher Cr+PCr before CBT had less severe OCD 
symptoms at follow-up; patients with lower Cr+PCr had more 
severe symptoms. A significant negative correlation was also 
seen between Cr+PCr and OCD symptom severity expressed by 
the Obsessive–Compulsive Index (r=−0.63, P,0.01). Higher 
pre-CBT Cr+PCr also predicted lower comorbid depressive 
(r=−0.71, P,0.001) and anxious (r=−0.68, P,0.001) symp-
toms at follow-up, as evaluated by the Montgomery–Åsberg 
Depression Rating Scale and the Hamilton Anxiety Rating 
Scale. Finally, pre-CBT Cr+PCr correlated negatively with 
the Sheehan Disability Score at follow-up (r=−0.75, P,0.001, 
not shown), meaning that greater disability was observed for 
patients with lower pretreatment Cr+PCr. Thus, low initial 
Cr+PCr in the pACC brain region presaged poor outcome on 
multiple clinical dimensions at least at one timepoint in the first 
post-treatment year. Similar findings (not shown) pertained for 
other MRS metabolites related to energy metabolism, such as 
choline compounds (Cho).
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Figure 3 Post-treatment (1–12 months) follow-up (f/u) clinical scores in a sample of 19 adult OCD patients (filled circles) who received 4 weeks of intensive daily CBT.
Notes: (A and B) Scores assayed core OCD symptoms on the Yale–Brown Obsessive Compulsive Scale (Y-BOCS, A) and Obsessive-Compulsive inventory (OCi, B). 
(C and D) Scores assayed depressive symptoms on the Montgomery–Åsberg Depression Rating Scale (MADRS, C) and anxious symptoms on the Hamilton Anxiety Rating 
Scale (HAMA, D). All scores are plotted as a function of the combined level (corrected for cerebrospinal fluid [CSF] content of the acquisition volume) of the energetic 
neurometabolites creatine (Cr) and phosphocreatine (PCr) in the midline (left + right) pregenual anterior cingulate cortex (pACC), a brain region linked to positive affect, 
among other functions. Levels were acquired with proton magnetic resonance spectroscopy (MRS) at most 1 week prior to CBT. Higher pretreatment levels of Cr+PCr 
were significantly correlated (Spearman) with lower OCD, depressive, and anxious symptoms across the sample. Thus, elevated energetic metabolism may dispose toward 
retention of response to CBT. This suggests that brain imaging may be helpful in predicting long-term outcomes in OCD.
Abbreviations: CBT, cognitive-behavioral therapy; CSF, cerebrospinal fluid; IU, Institutional Units; OCD, obsessive-compulsive disorder.
The precise physiological functions of the standard MRS 
neurometabolites are not firmly established, but we do have 
reasonable educated guesses. Cr and PCr together enable 
the short-term storage and release of cell-metabolic energy 
through the interchange of adenosine triphosphate and 
adenosine diphosphate.80 It is reasonable to think that higher 
combined Cr+PCr, measured by proton MRS, corresponds to 
greater buffering capacity, and thus greater ability to handle 
high energy throughout in the pACC. The pACC is implicated, 
among other functions, in regulation of positive emotional 
affect.81,82 It forms, for example, brain-reward circuits with 
the nucleus accumbens and thalamus.83 A possible predispos-
ing role for malfunctioning positive valence systems of the 
brain in OCD has been postulated.84 The dominant day-to-day 
affective tone in OCD is strongly negative, marked mainly 
by fear, worry, anxiety, perhaps at times by panic, but also, 
to degrees, by guilt, shame, regret and other ill feelings. In 
an, again speculative, interpretation of our findings, elevated 
Cr+PCr may reflect greater ability of the patient to experi-
ence and to be motivated by positive emotions and thereby 
to acclimate to life after CBT. Lower Cr+PCr in pACC may 
reflect less capacity to reorient thinking and behavior around 
positive motivations and thus may predispose a patient to 
slip back into pre-established OCD habits, ie, to relapse. In 
any case, these findings suggest an ability of regional MRS 
neurometabolites to predict post-CBT symptom severity and 
everyday functioning in OCD.
A neuroimaging research program 
to predict post-CBT outcome in 
OCD
Improved prediction of CBT response in OCD, particularly 
of long-term outcomes, could improve access to CBT by 
lowering the investment risks in terms of therapists’ and 
patients’ time and effort and reimbursement costs for third-
party payers. One possible pathway to seek these goals is the 
following. Although there is no guarantee that these goals can 
be achieved, building on the above-described research, this 
program outlines plausibly attainable next steps, not for the 
far, but for the immediate future. The first step is to validate 
predictive imaging results, such as our sample rsfMRI and 
MRS findings above, in larger patient groups, and using more 
Psychology Research and Behavior Management 2015:8submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
220
O’Neill and Feusner
regular and extended post-treatment follow-up intervals. We 
point out that the rsfMRI and MRS procedures described 
can each be carried out in approximately 10 minutes on con-
ventional MRI scanners. These scanners are already widely 
available at hospitals, medical research institutes, and local 
imaging centers in many areas. The next step is to identify 
endpoints (if such exist) that yield a cleaner and larger separa-
tion between relapsers and patients maintaining good response. 
Ie, the above findings are striking but, ideally and for clinical 
purposes, we desire a larger gap between subject groups with 
minimal overlap to reduce false positives and false negatives. 
This can be approached in at least two ways. The first is to 
test further metrics and combinations of metrics. For example, 
perhaps a non-path length or clustering coefficient-dependent 
graph theory metric, such as the participation coefficient, 
will perform better than small-worldness in discriminating 
groups. Or two graph theory metrics combined or two MRS 
metabolite levels or graph theory plus MRS. Collecting data 
from larger patient samples will open the field for this type 
of analytic experimentation and identification of optimum 
imaging endpoints. The second is that stratification (eg, by 
sex, age, severity, age-of-onset, and dimensional profile) of 
patient populations may lead to sharper distinctions between 
outcome groups on imaging indices. This will be enabled by 
studying larger overall samples. Once a clear and reliable pre-
dictive separation is established, as mentioned, the third step 
is to attain cross-scanner compatibility (eg, between Siemens 
and GE scanners) of the imaging endpoints. Thereafter, the 
path would not be far to clinical applicability. In patients free 
of MRI contraindications (eg, pacemakers and certain other 
implants), the rsfMRI and MRS scans described above can be 
acquired in 15–30 minutes using pulse sequences delivered 
with most scanners. The rsfMRI and MRS post-processing 
software we used above is available in streamlined commer-
cial or freely downloadable open-source packages with large 
and active user support communities. The procedures can be 
readily automated for operation by non-specialist clinicians. 
Ultimately, clinicians could use the predictions obtained in 
clinical decision-making. For example, those with high likeli-
hood of relapse or worsening of symptoms after CBT could be 
diverted to other forms of treatment instead such as medica-
tions or newer non-invasive and (for severe, refractory cases) 
invasive brain stimulation techniques (which, in kind, would 
benefit from similar lines of predictive research).
We emphasize that putative imaging predictors of CBT 
response represent only a partial and potential solution to 
the issue of access to CBT for OCD. Other solutions, such 
as training more therapists and developing alternative CBT 
modalities, should continue to be pursued. And again, no 
patient who wants CBT should be denied access to it simply 
because imaging indicators foresee a poor response. The main 
purpose of imaging predictors of response should be to help 
patients and clinicians better choose among their options. 
Moreover, current common practice of first exhausting safer 
treatments, including CBT, before resorting to invasive thera-
pies, such as deep brain stimulation or surgical resections, 
should remain even if highly accurate imaging predictors 
are established.
Conclusion
OCD is a widespread and often highly debilitating psychiatric 
condition, yet effective treatments are highly under-accessed. 
CBT is a first-line therapy for OCD, but is particularly 
underused. Many patients may prefer SRI medication 
because they are intimidated by the psychological challenges 
of CBT and/or reluctant to invest the work involved. Other 
barriers to access include the shortage of therapists trained 
in CBT, as well as the expense of CBT and difficulties with 
insurance coverage for the same. Group-CBT and Internet-
based CBT are emerging as effective practical responses 
to cost and therapist-shortage issues. A further innovative 
response might be improved prediction – perhaps with the aid 
of non-invasive neuroimaging – of long-term outcomes after 
CBT. In addition to lowering patient burden, more reliable 
outcome prediction would better justify cost reimbursement 
and would enable superior allocation of clinical resources. 
Pilot data from our laboratory were presented demonstrating 
that pretreatment endpoints derived from whole-brain rsfMRI 
analyzed using graph theory and MRS of the pACC brain 
region correlate with Y-BOCS and other clinical scores in 
post-CBT follow-up.
Acknowledgments
The authors wish to thank Karron Maidment, RN, MFT, and 
Lindsey Bergman, PhD, for informative discussion. This 
research is supported by NIMH awards R01MH085900 (JON/
JF) and R01MH081864 (JON and John Piacentini, PhD).
Disclosure
JDF is on the Scientific and Clinical Advisory Board of the 
International Obsessive–Compulsive Disorder Foundation. 
The authors report no other conflicts of interest in this work.
References
1. Bystritsky A, Munford PR, Rosen RM, et al. A preliminary study of 
partial hospital management of severe obsessive compulsive disorder. 
Psychiatr Serv. 1996;47(2):170–174.
Psychology Research and Behavior Management 2015:8 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
221
CBT access and post-treatment follow-up for OCD
 2. Calvocoressi L, McDougle CI, Wasylink S, Goodman WK, Trufan SJ, 
Price LH. Inpatient treatment of patients with severe obsessive-compul-
sive disorder. Hosp Community Psychiatry. 1993;44(12):1150–1154.
 3. Eddy KT, Dutra, Bradley R, Westen D. A multidimensional meta-
analysis of psychotherapy and pharmacotherapy for obsessive-
 compulsive disorder. Clin Psych Rev. 2004;24:1011–1030.
 4. Abramowitz JS. The psychological treatment of obsessive-compulsive 
disorder. Can J Psychiatry. 2006;51:407–416.
 5. Simpson HB, Huppert JD, Petkova E, Foa EB, Liebowitz MR. Response 
versus remission in obsessive-compulsive disorder. J Clin Psychiatry. 
2006;67(2):269–276.
 6. Eisen JL, Goodman WK, Keller MB, et al. Patterns of remission and 
relapse in obsessive-compulsive disorder: a 2-year prospective study. 
J Clin Psychiatry. 1999;60(5):346–352.
 7. Foa EB, Kozak MJ. Psychological treatment for obsessive-compulsive 
disorder. In: Mavissakalian M, Prien R, editors. Long-Term Treatments 
of Anxiety Disorders. Washington, DC: American Psychiatric Press, 
Inc.; 1996:285–309.
 8. Maina G, Albert U, Bogetto F. Relapses after discontinuation of 
drug associated with increased resistance to treatment in obsessive-
compulsive disorder. Int Clin Psychopharm. 2001;16(1):33–38.
 9. Ravizza L, Barzega G, Bellino S, Bogetto F, Maina G. Drug treat-
ment of obsessive-compulsive disorder (OCD): long-term trial with 
clomipramine and selective serotonin reuptake inhibitors (SSRIs). 
Psychopharm Bull. 1996;32(1):167–173.
 10. Romano S, Goodman W, Tamura R, Gonzales J, The Collabora-
tive Research Group. Long-term treatment of obsessive-compulsive 
disorder after an acute response: a comparison of fluoxetine versus 
placebo. J Clin Psychopharm. 2001;21(1):46–52.
 11. Simpson HB, Liebowitz MR, Foa EB, et al. Post-treatment effects of 
exposure therapy and clomipramine in obsessive compulsive disorder. 
Depress Anxiety. 2004;19(4):225–233.
 12. Simpson HB, Franklin ME, Cheng J, Foa EB, Liebowitz MR. Standard 
criteria for relapse are needed in obsessive-compulsive disorder. 
Depress Anxiety. 2005;21(1):1–8.
 13. Koran LM, Hanna GL, Hollander E, Nestadt G, Simpson HB, American 
Psychiatric Association. Practice guideline for the treatment of 
patients with obsessive-compulsive disorder. Am J Psychiatry. 2007; 
164(7 Suppl):5–53.
 14. Marques L, LeBlanc NJ, Weingarden HM, Timpano KR, Jenike M, 
Wilhelm S. Barriers to treatment and service utilization in an Internet 
sample of individuals with obsessive-compulsive symptoms. Depress 
Anxiety. 2010;27:470–475.
 15. Goodwin R, Koenen KC, Hellman F, Guardino M, Struening E. 
Helpseeking and access to mental health treatment for obsessive-
compulsive disorder. Acta Psychiatr Scand. 2002;106:143–149.
 16. Kohn DA, Saxena S, Levav I, Saraceno B. The treatment gap in mental 
health care. Bull World Health Organ. 2004;82:858–866.
 17. Schwartz C, Schlegl S, Kuelz AK, Voderholzer U. Treatment-seeking in 
OCD community cases and psychological treatment actually provided to 
treatment-seeking patients: a systematic review. J Obsessive Compuls 
Relat Disord. 2013;2448–2456.
 18. Blanco C, Olfson M, Stein DJ, Simpson HB, Gameroff MJ, Narrow WH. 
Treatment of obsessive-compulsive disorder by US psychiatrists. 
J Clin Psychiatry. 2006;67:946–951.
 19. Torres AR, Prince MJ, Bebbington PE, et al. Treatment seeking by 
individuals with obsessive-compulsive disorder from the British psy-
chiatric morbidity survey of 2000. Psychiatr Serv. 2007;58:977–982.
 20. American Psychiatric Association. Diagnostic and Statistical Manual 
of Mental Disorders: DSM-5. Washington, DC: American Psychiatric 
Association; 2013.
 21. Taylor CB, Chang VY. Issues in the dissemination of cognitive-behavior 
therapy. Nord J Psychiatry. 2008;62:37–44.
 22. Larsson BPM, Kaldo V, Broberg AG. Similarities and differences 
between practitioners of psychotherapy in Sweden: a comparison of 
attitudes between psychodynamic, cognitive, cognitive-behavioral, and 
integrative therapists. J Psychother Integr. 2009;19(1):34–66.
 23. Mataix-Cols D, Marks IM. Self-help with minimal therapist contact 
for obsessive-compulsive disorder: a review. Eur Psychiatry. 2006;21: 
75–80.
 24. Shapiro DA, Cavanagh K, Lomas H. Geographic inequity in the avail-
ability of cognitive behavioural therapy in England and Wales. Behav 
Cog Psychother. 2003;31:185–192.
 25. Valderhaug R, Götestam K, Larsson B. Clinicians’ views on manage-
ment of obsessive-compulsive disorders in children and adolescents. 
Nord J Psychiatry. 2004;58:125–132.
 26. Anderson RA, Rees CS. Group versus individual cognitive-behavioural 
treatment for obsessive-compulsive disorder: a controlled trial. Behav 
Res Ther. 2007;45:123–137.
 27. Belotto-Silva C, Diniz JB, Malavazzi DM, et al. Group cognitive-
behavioral therapy versus selective serotonin reuptake inhibitors for 
obsessive-compulsive disorder: a practical clinical trial. J Anxiety 
Disord. 2012;26:25–31.
 28. Bouvard M, Milliery M, Cottraux J. Un programme de thérapie cognitive 
et comportementale en groupe dans le trouble obsessionnel compulsif: 
résultats préliminaires. Encéphale. 2002;28(5 Pt 1):439–446.
 29. Braga DT, Gus Manfro G, Niederauer K, Cordiolo AV. Full remis-
sion and relapse of obsessive-compulsive symptoms after cognitive- 
behavioral group therapy: a two-year follow-up. Rev Bras Psiquiatria. 
2010;32(2):164–168.
 30. Farrell L, Waters A, Milliner E, Ollendick T. Comorbidity and treatment 
response in pediatric OCD: a pilot study of group cognitive-behavioral 
treatment. Psychiatry Res. 2012;199(2):115–123.
 31. Andersson E, Enander J, Andrén P, et al. Internet-based cognitive 
behaviour therapy for obsessive-compulsive disorder: a randomized 
controlled trial. Psychol Med. 2012;42:2193–2203.
 32. Andersson E, Ljótsson B, Hedman E, et al. Internet-based cognitive 
behavior therapy for obsessive compulsive disorder: a pilot study. BMC 
Psychiatry. 2011;11:125–135.
 33. Klein B, Meyer D, Austin DW, Kyrios M. Anxiety Online – A virtual 
clinic: preliminary outcomes following completion of five fully auto-
mated treatment programs for anxiety disorders and symptoms. J Med 
Internet Res. 2011;13(4):e89.
 34. Lenhard F, Vigerland S, Andersson E, et al. Internet-delivered cognitive 
behavior therapy for adolescents with obsessive-compulsive disorder: 
an open trial. PLoS One. 2014;9(6):e100773.
 35. Storch EA, Caporino NE, Morgan JR, et al. Preliminary investiga-
tion of web-camera delivered cognitive-behavioral therapy for youth 
with obsessive-compulsive disorder. Psychiatry Res. 2011;189: 
407–412.
 36. Turner CM, Matiax-Cols D, Lovell K, et al. Telephone cognitive-
behavioral therapy for adolescents with obsessive-compulsive disorder: 
a randomized controlled non-inferiority trial. J Am Acad Child Adol 
Psychiatry. 2014;53(12):1298–1307.
 37. Hiss H, Foa EB, Kozak MJ. Relapse prevention program for treatment 
of obsessive-compulsive disorder. J Consult Clin Psych. 1994;62(4): 
801–808.
 38. Kirk JW. Behavioural treatment of obsessional-compulsive patients in 
routine clinical practice. Behav Res Ther. 1983;21(1):57–62.
 39. Meyer V. Modification of expectations in cases with obsessional rituals. 
Behav Res Ther. 1966;4(4):273–280.
 40. Neziroglu F, Henricksen J, Yaryura-Tobias JA. Psychotherapy of 
obsessive-compulsive disorder and spectrum: established facts and 
advances, 1995–2005. Psychiatr Clin North Am. 2006;29(2):585–604.
 41. O’Sullivan G, Noshirvani H, Marks I, Monteiro W, Lellott P. Six-year 
follow-up after exposure and clomipramine therapy for obsessive 
compulsive disorder. J Clin Psychiatry. 1991;52(4):150–155.
 42. Riggs D, Foa EB. Obsessive compulsive disorder. In: Barlow DH, 
editor. Clinical Handbook of Psychological Disorders: A Step-by-
Step Treatment Manual. 2nd ed. New York: Guilford Press; 1993: 
189–239.
 43. Steketee G, Foa EB, Grayson JB. Recent advances in the behavioral 
treatment of obsessive-compulsives. Arch Gen Psychiatry. 1982;39(12): 
1365–1371.
Psychology Research and Behavior Management 2015:8submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
222
O’Neill and Feusner
 44. Pallanti S, Hollander E, Bienstock C, et al. Treatment non-response 
in OCD: methodological issues and operational definitions. Int J 
Neuropsychopharm. 2002;5(2):181–191.
 45. Koran LM, Hackett E, Rubin A, Wolkow R, Robinson D. Efficacy of 
sertraline in the long-term treatment of obsessive-compulsive disorder. 
Am J Psychiatry. 2002;159(1):88–95.
 46. Hollander E, Paroxetine OCD Study Group, Allen A, et al. Acute and 
long-term treatment and prevention of relapse of obsessive-compulsive 
disorder with paroxetine. J Clin Psychiatry. 2003;64(9):1113–1121.
 47. Hollander E, Stein DJ, Fineberg NA, Marteau F, Legault M. Quality 
of life outcomes in patients with obsessive-compulsive disorder: 
Relationship to treatment response and symptom relapse. J Clin 
 Psychiatry. 2010;71(6):784–792.
 48. Fineberg NA, Tonnoir B, Lemming O, Stein DJ. Escitalopram prevents 
relapse of obsessive-compulsive disorder. Eur Neuropsychopharm. 
2007;17(6–7):430–439.
 49. Foa EB, Liebowitz MR, Kozak MJ, et al. Randomized, placebo-
controlled trial of exposure and ritual prevention, clomipramine, and 
their combination in the treatment of obsessive-compulsive disorder. 
Am J Psychiatry. 2005;162(1):151–161.
 50. Keeley ML, Storch EA, Merlo LJ, Gefken GR. Clinical predictors of 
response to cognitive-behavioral therapy for obsessive–compulsive 
disorder. Clin Psychol Rev. 2008;28:118–130.
 51. Raffin AL, Ferrão YA, Pasquoto de Souza F, Cordioli AV. Fatores predi-
tores de resultados no tratamento do transtorno obsessivo-compulsivo com 
as terapias comportamental e cognitivo-comportamental: uma revisão 
sistemática. Rev Psiquiatria do Rio Grande do Sul. 2008;30(1 Suppl): 
1–20.
 52. Knopp J, Knowles S, Bee P, Lovell K, Bower P. A systematic review 
of predictors and moderators of response to psychological therapies in 
OCD: do we have enough empirical evidence to target treatment? Clin 
Psych Rev. 2013;33:1067–1081.
 53. Eisen JL, Pinto A, Mancebo MC, Dyck IR, Orlando ME, Rasmussen SA. 
A 2-year prospective follow-up study of the course of obsessive-
compulsive disorder. J Clin Psychiatry. 2010;71(8):1033–1039.
 54. Lewin AB, Wu MS, McGuire JF, Storch EA. Cognitive behavior therapy 
for obsessive-compulsive and related disorders. Psychiatr Clin North 
Am. 2014;37(3):415–445.
 55. Bloch MH, Green C, Kichuk SA, et al. Long-term outcome in adults with 
obsessive-compulsive disorder. Depress Anxiety. 2013;30(8):716–722.
 56. Eisen JL, Sibrava NJ, Boisseau CL, et al. Five-year course of obsessive-
compulsive disorder: Predictors of remission and relapse. J Clin 
 Psychiatry. 2013;74(3):233–239.
 57. Fineberg NA, Hengartner MP, Bergbaum C, Gale T, Rössner W, 
Angst J. Remission of obsessive-compulsive disorders and syndromes; 
evidence from a prospective community cohort study over 30 years. 
Int J Psychiatry Clin Pract. 2013;17(3):179–187.
 58. Jakubovski E, Diniz JB, Valerio C, et al. Clinical predictors of long-
term outcome in obsessive-compulsive disorder. Depress Anxiety. 2013; 
30(8):763–772.
 59. Rufer M, Hand I, Alsleben H, et al. Long-term course and outcome of 
obsessive-compulsive patients after cognitive-behavioral therapy in 
combination with either fluvoxamine or placebo: a 7-year follow-up of 
a randomized double-blind trial. Eur Arch Psychiatry Clin Neurosci. 
2005;255(2):121–128.
 60. Stewart SE, Geller DA, Jenike M, et al. Long-term outcome of pediatric 
obsessive-compulsive disorder: a meta-analysis and qualitative review 
of the literature. Acta Psychiatr Scand. 2004;110(1):4–13.
 61. Farris SG, McLean CP, Van Meter P, Simpson HB, Foa EB. Comorbidity 
and treatment response in pediatric OCD: a pilot study of group cognitive-
behavioral treatment. J Clin Psychiatry. 2013;74(7):685–690.
 62. Gerber AJ, Peterson BS. What is an image? J Am Acad Child Adolesc 
Psychiatry. 2008;47(3):245–248.
 63. Maia TV, Cooney RE, Peterson BS. The neural bases of obsessive–
compulsive disorder in children and adults. Dev Psychopathol. 2008;20: 
1251–1283.
 64. Menzies L, Chamberlain SR, Laird AR, Thelen SM, Sahakian BJ, 
Bullmore ET. Integrating evidence from neuroimaging and neuropsy-
chological studies of obsessive-compulsive disorder: the orbitofronto-
striatal model revisited. Neurosci Biobehav Rev. 2008;32:525–549.
 65. Cole MW, Bassett DS, Power JD, Braver TS, Petersen SE. Intrinsic and 
task-evoked network architectures of the human brain. Neuron. 2014; 
83:238–251.
 66. Doidge N. The Brain that Changes Itself. New York: Viking Press; 
2007.
 67. Stern ER, Fitzgerald KD, Welsh RC, Abelson JL, Taylor SF. 
Resting-state functional connectivity between fronto-parietal and 
default mode networks in obsessive-compulsive disorder. PLoS One. 
2012;7(5):e36356.
 68. van den Heuvel OA, Veltman DJ, Groenewegen HJ, et al. Frontal-striatal 
dysfunction during planning in obsessive-compulsive disorder. Arch 
Gen Psychiatry. 2005;62:301–310.
 69. Brennan BP, Rauch SL, Jensen JE, Pope HG Jr. A critical review of 
magnetic resonance spectroscopy studies of obsessive-compulsive 
disorder. Biol Psychiatry. 2013;73(1):24–31.
 70. O’Neill J, Piacentini JC, Chang S, et al. MRSI correlates of cognitive-
behavioral therapy in pediatric obsessive-compulsive disorder. Prog 
Neuropsychopharmacol Biol Psychiatry. 2012;36:161–168.
 71. Saxena S, Gorbis E, O’Neill J, et al. Rapid effects of brief intensive 
cognitive-behavioral therapy on brain glucose metabolism in obsessive-
compulsive disorder. Mol Psychiatry. 2009a;14(2):197–205.
 72. Saxena S, O’Neill J, Rauch S. The role of cingulate cortex dysfunc-
tion in obsessive-compulsive disorder. In: Vogt BA, editor. Cingulate 
Neurobiology and Disease. New York: Oxford University Press; 
2009b:587–617.
 73. O’Neill J, Gorbis E, Feusner JD, et al. Effects of intensive cognitive-
 behavioral therapy on cingulate neurochemistry in obsessive- compulsive 
disorder. J Psychiatry Res. 2013;47(4):494–504.
 74. Feusner J, Moody T, Lai TM, et al. Brain connectivity and prediction 
of relapse after cognitive-behavioral therapy in obsessive-compulsive 
disorder. Front Psychiatry. 2015;6:74.
 75. Bullmore E, Sporns O. Complex brain networks: graph theoretical 
analysis of structural and functional systems. Nat Rev Neurosci. 2009; 
10(3):186–198.
 76. Watts DJ, Strogatz SH. Collective dynamics of ‘small-world’ networks. 
Nature. 1998;393(6684):440–442.
 77. Zhang T, Wang J, Yang Y, et al. Abnormal small-world architecture 
of top–down control networks in obsessive–compulsive disorder. 
J Psychiatry Neurosci. 2011;36(1):23–31.
 78. Shin DJ, Wi HJ, He Y, et al. The effects of pharmacological treatment 
on functional brain connectome in obsessive-compulsive disorder. Biol 
Psychiatry. 2014;75(8):606–614.
 79. Provencher SW. Automatic quantitation of localized in vivo 1H spectra 
with LCModel. NMR Biomed. 2001;14(4):260–264.
 80. Erecinska M, Silver IA. ATP and brain function. J Cereb Blood Flow 
Metab. 1989;9(1):2–19.
 81. Vogt BA. Pain and emotion interactions in subregions of the cingulate 
gyrus. Nat Rev Neurosci. 2005;6(7):533–544.
 82. Vogt BA. Regions and subregions of the cingulate gyrus. In: Vogt 
BA, editor. Cingulate Neurobiology and Disease. New York: Oxford 
University Press; 2009.
 83. Berridge KC, Kringelbach ML. Affective neuroscience of pleasure: reward 
in humans and animals. Psychopharmacolgy (Berl). 2008;199:457–480.
 84. Aouizerate B, Guehl D, Cuny E, et al. Pathophysiology of obsessive– 
compulsive disorder: a necessary link between phenomenology, neuropsy-
chology, imagery and physiology. Prog Neurobiol. 2004;72:195–221.
Psychology Research and Behavior Management
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/psychology-research-and-behavior-management-journal
Psychology Research and Behavior Management is an international, peer-
reviewed, open access journal focusing on the science of psychology and 
its application in behavior management to develop improved outcomes 
in the clinical, educational, sports and business arenas. Specific topics 
covered include: Neuroscience, memory & decision making; Behavior 
modification & management; Clinical applications; Business & sports 
performance management; Social and developmental studies; Animal 
studies. The manuscript management system is completely online and 
includes a quick and fair peer-review system. Visit http://www.dovepress.
com/testimonials.php to read real quotes from published authors.
Psychology Research and Behavior Management 2015:8 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
Dovepress
223
CBT access and post-treatment follow-up for OCD
